A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors
Status:
Recruiting
Trial end date:
2030-01-31
Target enrollment:
Participant gender:
Summary
This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part
of your body like your lungs or liver instead of your blood. Once they've grown bigger in one
spot or spread to other parts of the body, they're harder to treat. This is called advanced
or metastatic cancer.
Participants in this study must have breast cancer or gastric cancer. Participants must have
tumors that have HER2 on them. This allows the cancer to grow more quickly or spread faster.
There are few treatment options for patients with advanced or metastatic solid tumors that
express HER2.
This clinical trial uses an experimental drug called disitamab vedotin (DV). Disitamab
vedotin is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer
cells and kill them.
This clinical trial uses a drug called tucatinib, which has been approved to treat cancer in
the United States and some other countries. This drug is sold under the brand name TUKYSA®.
This study will test how safe and how well DV, with or without tucatinib, is for participants
with solid tumors. This study will also test what side effects happen when participants take
these drugs. A side effect is anything a drug does to the body besides treating the disease.